Status:
TERMINATED
Doxil and Gemcitabine in Recurrent Ovarian Cancer
Lead Sponsor:
Women and Infants Hospital of Rhode Island
Collaborating Sponsors:
Ortho Biotech, Inc.
Conditions:
Ovarian Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lowe...
Detailed Description
This study will evaluate the toxicities of Doxil and Gemcitabine given on an every two week basis. Our hypothesis is that toxicity will be less than that with standard dosing without any negative effe...
Eligibility Criteria
Inclusion
- recurrent platinum resistant ovarian cancer
- measurable disease
Exclusion
- prior treatment with Doxil or Gemzar
- life expectancy \<3months
- cardiac ejection fraction \<50%
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00312650
Start Date
April 1 2006
End Date
May 1 2006
Last Update
January 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women and Infants' Hospital
Providence, Rhode Island, United States, 02905